This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Adverum Biotechnologies, Inc (ADVM) is expected to report fourth-quarter 2016 results on Mar 2.
Intrexon (XON): Will the Stock Pull a Surprise in Q4 Earnings?
by Zacks Equity Research
Intrexon Corporation (XON) is scheduled to report fourth-quarter 2016 results on Mar 1, after the market closes.
Why Tesaro (TSRO) Might Surprise This Earnings Season
by Zacks Equity Research
Tesaro (TSRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Universal Health (UHS) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Universal Health Services, Inc. (UHS) will release fourth-quarter 2016 results on Feb 28, after the market closes. Last quarter, the company posted a negative earnings surprise of 4.19%.
Tenet Healthcare (THC) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Tenet Healthcare Corporation (THC) will release fourth-quarter 2016 results on Feb 27, after the market closes. Let's see how things are shaping up for this announcement.
Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Endocyte, Inc (ECYT) is expected to report fourth-quarter 2016 results on Mar 1. The company has an impressive track record, having beaten estimates on three of the trailing four quarters and reporting in-line results in the remaining quarter
Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?
by Zacks Equity Research
Horizon Pharma plc (HZNP) is scheduled to report fourth-quarter 2016 results on Feb 27, before the opening bell.
Endo (ENDP) to Post Q4 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Endo International plc (ENDP) is scheduled to report fourth-quarter 2016 results on Feb 28, before the opening bell.
Intercept (ICPT) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report fourth-quarter 2016 results on Feb 23.
Are Options Traders Betting on a Big Move in Tesaro (TSRO) Stock?
by Zacks Equity Research
Investors in Tesaro, Inc. (TSRO) need to pay close attention to the stock based on moves in the options market lately.
TESARO Varubi IV Gets Complete Response Letter in the U.S.
by Zacks Equity Research
TESARO (TSRO) announced that it has received a Complete Response Letter from the FDA regarding its NDA for Varubi IV.
The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen
4 Biotech Stocks that More than Doubled in 2016
by Arpita Dutt
Despite the immense pressure on the sector, there were some biotech stocks that bucked the trend and more than doubled in 2016.
5 Healthcare Stocks Poised to Trump Q3 Earnings
by Zacks Equity Research
Medical is one of the many sectors that is witnessing earnings and revenue growth this quarter.